Also known as: LOXO-292, Retevmo
Selpercatinib is marketed as RETEVMO, a selective RET-targeted kinase inhibitor indicated across RET fusion-positive NSCLC, RET-mutant medullary thyroid cancer, RET fusion-positive thyroid cancer, and other RET fusion-positive solid tumors. Labeling includes both adult and pediatric indications for patients aged 2 years and older in several settings. U.S. initial approval was in 2020.
An experimental immunotherapy drug shows tumor shrinkage in prostate cancer patients, while Eli Lilly's selpercatinib reduces recurrence risk in early-stage lung cancer. A separate study reveals persistent racial disparities in curative treatment for lung cancer patients.
Eli Lilly announced positive Phase 3 results for EBGLYSS in pediatric atopic dermatitis, orforglipron in diabetes showing superiority over Rybelsus, and Retevmo in early-stage lung cancer, expanding potential indications across its portfolio.
Eli Lilly is preparing for the launch of oral weight loss pill Orforglipron with a US$3 billion, decade-long investment in China, while advancing its oncology and genetic medicine pipeline with positive Phase 3 results for Retevmo and a milestone in CRISPR collaboration.
The global oncology market is projected to nearly triple from $279.98 billion in 2026 to $748.17 billion by 2035, driven by rapid adoption of immunotherapy, checkpoint inhibitors, and cell therapies across solid tumors and hematologic cancers.
Phase 3 LIBRETTO-432 trial met its primary endpoint, showing selpercatinib delivered statistically significant and clinically meaningful improvement in event-free survival versus placebo as adjuvant therapy in early-stage RET fusion-positive NSCLC.
Eli Lilly has stockpiled $1.5 billion in inventory for Orforglipron ahead of an expected FDA decision in April. The oral weight-loss pill aims to compete with Novo Nordisk's recently approved oral Wegovy.
Eli Lilly's Retevmo (selpercatinib) demonstrated statistically significant event-free survival improvement in the Phase III LIBRETTO-432 trial for early-stage RET fusion-positive non-small cell lung cancer.
Eli Lilly's Retevmo demonstrated statistically significant improvement in event-free survival versus placebo in stage II-IIIA RET fusion-positive non-small cell lung cancer following curative therapy in the phase 3 LIBRETTO-432 trial.
Eli Lilly announced positive Phase 3 LIBRETTO-432 trial results showing Retevmo (selpercatinib) significantly improved event-free survival in patients with early-stage RET fusion-positive non-small cell lung cancer as adjuvant therapy.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07543887 |
Selpercatinib and Body Composition |
COMPLETED | |
| NCT07146893 |
Feasibility Study for Repurposing RET Inhibitors |
NOT_YET_RECRUITING | EARLY_PHASE1 |
| NCT07010393 |
Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study |
NOT_YET_RECRUITING | PHASE4 |
| NCT06532149 |
ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer |
RECRUITING | |
| NCT05906836 |
A Drug Drug Interaction (DDI) Study of Selpercatinib (LY3527723) and Rosuvastatin in Healthy Participants |
COMPLETED | PHASE1 |
| NCT05668962 |
Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC |
RECRUITING | PHASE2 |
| NCT05630287 |
A Study of Absorption, Metabolism, Excretion, and Absolute Bioavailability of Carbon-14-Labelled [14C] Selpercatinib (LY3527723) in Healthy Male Participants |
COMPLETED | PHASE1 |
| NCT05630274 |
A Study of Effect of Selpercatinib (LY3527723) on Corrected QT (QTc) Interval in Healthy Participants |
COMPLETED | PHASE1 |
| NCT05469113 |
A Study of Effects of Selpercatinib (LY3527723) on Repaglinide in Healthy Participants |
COMPLETED | PHASE1 |
| NCT05469100 |
A Study of Effect of Selpercatinib (LY3527723) in Participants With Normal and Impaired Renal Function |
COMPLETED | PHASE1 |
